125104-34-9

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-formylisonicotinate is used as a key intermediate for the synthesis of various drugs, particularly those targeting cardiovascular diseases and diabetes. Its role in the production of these drugs is crucial due to its ability to contribute to the development of effective treatments for these health conditions.
Used in Medical Industry:
In the medical industry, Methyl 2-formylisonicotinate is utilized as a building block in the creation of pharmaceutical products that address a range of health issues. Its chemical properties and reactivity make it an essential component in the formulation of medications that improve patient outcomes.
Used in Organic Compound Production:
Methyl 2-formylisonicotinate is also used in the production of other organic compounds, highlighting its versatility and applicability in various chemical processes. Its role in the synthesis of these compounds contributes to the development of a wide range of products across different industries.
Used in Synthesis of Biologically Active Molecules:
Methyl 2-formylisonicotinate plays a significant role in the synthesis of biologically active molecules, which are essential in the development of new pharmaceuticals and medical products. Its contribution to this process is vital for advancing research and innovation in the medical field.

Upstream product

• 25658-36-0 pyridine-2,4-dicarboxylic acid dimethyl ester 
• 58481-17-7 methyl 2-(hydroxymethyl)pyridine-4-carboxylate 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 

Downstream Products

• 1251844-44-6 methyl 2-(difluoromethyl)isonicotinate 
• 1372144-57-4 1-(methoxycarbonyl)-2-(morpholinomethyl)piperidine-4-carboxylic acid 

Relevant academic research and scientific papers

HISTONE DEMETHYLASE INHIBITORS

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject

ISOXAZOL-3(2H)-ONE ANALOGS AS PLASMINOGEN INHIBITORS AND THEIR USE IN THE TREATMENT OF FIBRINOLYSIS RELATED DISEASES

A compound of formula (I): wherein R1 is hydrogen; R2 is C1-C10 alkyl, which C1-C10 alkyl comprises 0, 1, 2, 3 or 4 heteroatoms, selected from O and N, or 0, 1 or 2 acid, ester or amide functionalities, and said C1-C10 alkyl is substituted by 0, 1, 2, 3 or 4 CH3, halogen or CF3, or -XR20, wherein X is a bond or _-CH2-, and R20 is a 4 to 10 membered, monocyclic or bicyclic heterocyclic aromatic or non-aromatic ring containing 1, 2, 3 or 4 heteroatoms selected from O and N, and R20 is substituted by 0, 1, 2, 3 or 4 CH3, halogen or CF3, pharmaceutical compositions, medical uses and treatment or prophylaxis of a disease or condition in which modulation of fibrinolysisis is beneficial.

Calcitonin gene-related peptide (CGRP) receptor antagonists: Pyridine as a replacement for a core amide group

In our continuing efforts to identify CGRP receptor antagonists that can be dosed orally for the treatment of migraine headache, we have investigated a pyridine bioisosteric replacement of a polar amide portion of a previous lead compound, BMS-694153. Pyr

ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS

or a pharmaceutically suitable salt thereof, wherein, R1 and R2 independently are hydrogen, deuterium, aryl, hetero aryl, C1-C8 alkyl, optionally being substituted with one or more substituents independently being R3,R3 is an aryl, hetero aryl, fluorine(s), a C1-C6 alkyl containing one or more fluorine, a C1-C6 alkyl containing one or more deuterium, a C1-C6 alkyl containing hydroxy, the aryl and heteroaryl optionally being substituted with one or more halogen, a fluorinated alkoxy, a fluorinated alkyl, a sulfonyl, one or more deuterium, a C1-6 alkyl, a C1-6 alkoxy, a nitrile,or R3 is a C1-6 alkyl optionally substituted with one or more of the following groups: COOR4, OCOR4, CONR5R6, NR5COR6, OR4;wherein, R4 is a C1-10 alkyl optionally substituted with one or more fluorine, deuterium, alkoxy, arylcarboxylate, alkyl carboxylate;R5 and R6 are independently selected from hydrogen, alkyl or they may together form a 4-8 membered carbon ring;or R1 and R2 form a 3-10 membered carbon ring optionally comprising O or N and optionally substituted with a C1-10 alkyl or aryl, hetero aryl optionally substituted with R3.

Gonadotropin releasing hormone receptor antagonists

The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists.

Cholinesterase reactivators derived from pyridine-2-carbaldoxime

Monoquaternary reactivators of cholinesterase 3a-3c were prepared by quaternization of substituted pyridine-2-carbaldoximes with an ester (1a, 1b) or carbamoyl (2) function in position 4. A new bisquaternary reactivator, 4-carbamoyl-2′-[(hydroxyimino)methyl]-1,1′-(but-2-ene-1,4-diyl) bispyridinium salt (5), was derived from the unsubstituted pyridine-2-carbaldoxime. The compounds were characterized by UV spectra and ionization constants. The substances exhibit antidote effects in intoxications with organophosphate cholinesterase inhibitors.